後天性再生不良性貧血の世界市場：市場規模（種類別・用途別・地域別）、将来予測

後天性再生不良性貧血の市場規模と予測

後天性再生不良性貧血市場は、予測期間中（すなわち2024年から2032年まで）に顕著なCAGRで収益と指数関数的な市場成長を開発すると予想されます。

後天性再生不良性貧血市場規模の成長は、主に血液疾患の有病率の増加、資金調達、医療保険の適用、血液疾患に対する意識向上プログラムに起因しています。「世界の後天性再生不良性貧血市場」レポートは、市場の全体的な評価を提供します。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

世界の後天性再生不良性貧血市場の定義

後天性再生不良性貧血は稀な重篤な血液疾患であり、骨髄の機能不全と血液細胞の産生不能を特徴とします。骨髄は骨の中心にあり、スポンジ状の物質のように見えます。骨髄は他の血液成分とともに赤血球を産生する役割を担っています。再生不良性貧血には、後天性再生不良性貧血と遺伝性再生不良性貧血の2つの症状があります。後天性再生不良性貧血の方が一般的で、一時的なものであることもあるが、遺伝性再生不良性貧血に比べるとまれな疾患です。

後天性再生不良性貧血の原因には、農薬、ヒ素、ベンゼンなどの毒物、放射線や化学療法、肝炎、エプスタイン・バーウイルス、サイトメガロウイルス、パルボウイルスB19、HIVなどの感染症などがあります。また、ループスや関節リウマチなどの自己免疫疾患もあります。体の他の部位にできたがんが骨に転移し、後天性再生不良性貧血を起こすこともあります。この病気は主に小児、10代、若年成人に発症します。この疾患には支持療法があり、その治療法は重症度によって異なります。

世界の後天性再生不良性貧血市場の概要

血液疾患の有病率の増加が、世界の再生不良性貧血市場を牽引すると予想されます。例えば、米国疾病予防管理センターによると、血友病Aは男性の新生児5,000人に1人が罹患し、毎年約400人の赤ちゃんが血友病Aで生まれています。さらに、再生不良性貧血や血液疾患に対する意識の高まりが、世界市場の成長を促進すると考えられます。

例えば、The Aplastic Anemia and MDS International Foundation、NORD-National Organization for Rare Disorders, Inc.、CancerIndexなどが再生不良性貧血に関する認知を広めています。2019年2月には、再生不良性貧血トラスト春の啓発キャンペーンが開始されました。さらに、研究開発に対する政府支援の増加、ライフスタイルの変化、技術の急速な開拓は、予測期間中の市場成長を促進すると予想されます。

さらに、希少疾患の有病率の増加、より良い治療に対する需要の高まり、研究開発のためのバイオテクノロジーや製薬業界への投資の増加、資金の確保が市場の成長を後押ししています。しかし、治療費の高騰が予測期間中の市場成長を鈍化させる可能性があります。治療費は治療法の選択に影響を与える主要因です。骨髄移植の費用は米国で30万米ドル以上です。したがって、治療費の高さが再生不良性貧血治療市場の成長を妨げる可能性が高いです。

目次

第1章 世界の後天性再生不良性貧血市場：イントロダクション

• 市場概要
• 分析範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの分析手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の後天性再生不良性貧血市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 世界の後天性再生不良性貧血市場：種類別

• 概要
• 診断
• 治療

第6章 世界の後天性再生不良性貧血市場：用途別

• 概要
• 病院
• 診療所
• その他

第7章 世界の後天性再生不良性貧血市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋
• 世界のその他の地域
  • ラテンアメリカ
  • 中東

第8章 世界の後天性再生不良性貧血市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第9章 企業プロファイル

• Pfizer Inc.
• Bayer AG
• Novo Nordisk AS
• Shire
• SOBI
• Octapharma
• CSL Limited
• Amgen Inc.
• GlaxoSmithKline plc.
• Bluebird bio

第10章 付録

• 関連分析

Acquired Aplastic Anemia Market Size And Forecast

Acquired Aplastic Anemia Market is expected to develop revenue and exponential market growth at a remarkable CAGR during the forecasted period i.e. 2024 to 2032.

The Acquired Aplastic Anemia market size growth is majorly attributed to the increasing prevalence of blood disorders, raising funding, healthcare insurance coverage, and awareness programs for blood disorders. The Global Acquired Aplastic Anemia Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Acquired Aplastic Anemia Market Definition

Acquired Aplastic Anemia is a rare, serious blood disorder, which is characterized by failure of the bone marrow and its inability to produce blood cells. Bone marrow is found in the center of the bones and appears to be like a spongy substance. It is responsible for the production of red blood cells along with other blood components. Aplastic anemia has two manifestations, i.e. Acquired Aplastic Anemia and inherit aplastic anemia Acquired Aplastic Anemia is more common, and sometimes it's only temporary whereas, it is a rare disorder as compared to inherit aplastic anemia.

Various causes of Acquired Aplastic Anemia include toxins, such as pesticides, arsenic, and benzene, radiation and chemotherapy treatments, infectious diseases, such as hepatitis, Epstein-Barr virus, cytomegalovirus, parvovirus B19, and HIV. And autoimmune disorders, such as lupus and rheumatoid arthritis. Sometimes, cancer from another part of the body can spread to the bone and cause Acquired Aplastic Anemia. The disease occurs mainly in children, teenagers and young adults. The supportive treatments of this disease are available, which depend on the severity of the condition.

Global Acquired Aplastic Anemia Market Overview

An increase in the prevalence of blood disorders is anticipated to drive the global aplastic anemia market. For instance, according to the Centers for Disease Control and Prevention, in the U.S., haemophilia A affects 1 in 5,000 male newborns and about 400 babies are born with haemophilia A each year; an estimated incidence of hemophilia is 1 per 12,000 annually. In addition, an increase in awareness about aplastic anemia and blood disorders is likely to fuel the growth of the global market.

For instance, The Aplastic Anemia and MDS International Foundation, NORD - National Organization for Rare Disorders, Inc., and CancerIndex, among others, are spreading awareness about aplastic anemia. In February 2019, The Aplastic Anemia Trust spring awareness Campaign was launched. Furthermore, increasing government support for research & development, changing lifestyle, and rapidly developing technology is expected to fuel the market growth during the forecast period.

Moreover, the Increasing prevalence of rare diseases, rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R&D, and availability of funds drive the growth of the market. However, the high cost of the treatment may slow the market growth during the period. The cost of treatment is a major factor influencing the selection of the treatment. The cost of a bone marrow transplant is more than US$ 300,000. Thus, the high cost of the treatment is likely to hamper the growth of the aplastic anemia treatment market.

Global Acquired Aplastic Anemia Market: Segmentation Analysis

The Global Acquired Aplastic Anemia Market is segmented based on Type, Application, and Geography.

Acquired Aplastic Anemia Market, By Type

• Diagnosis
• Treatment

Based on Type, the market is bifurcated into Diagnosis and Treatment. The Treatment segment is expected to inflate the market growth.

Acquired Aplastic Anemia Market, By Application

• Hospitals
• Clinics
• Others
• Acquired Aplastic Anemia Market By Application

Based on Application, the market is bifurcated into Hospitals, Clinics, Other. Hospitals are anticipated to become the fastest-growing market in the forecast duration.

Acquired Aplastic Anemia Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of regional analysis, the Global Acquired Aplastic Anemia Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America dominate the global Acquired Aplastic Anemia market owing to well-developed technology, increasing patient with blood disorders, increasing prevalence of cancer, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Key Players

The "Global Acquired Aplastic Anemia Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Pfizer Inc., Bayer AG, Novo Nordisk AS, Shire, SOBI, Octapharma, CSL Limited, Amgen Inc., GlaxoSmithKline plc., and Bluebird bio. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In June 2021, Heartseed and Novo Nordisk will enter into a global collaboration and licensing agreement for stem cell-based heart failure therapy. Except for Japan, Novo Nordisk will have exclusive rights to develop, manufacture, and commercialize HS-001 internationally. Heartseed will retain the exclusive rights to develop HS-001 in Japan, while Novo Nordisk will co-commercialize the product with Heartseed in Japan on a 50/50 profit and cost-sharing basis.
• The Food and Drug Administration approved Novartis AG's Promacta as a first-line treatment for aplastic anemia in November 2018.
• Mergers and Acquisitions
• Amgen announced on April 16, 2021, that it had completed its previously announced tender offer to buy all outstanding shares of common stock of Five Prime Therapeutics, a clinical-stage biotechnology firm focused on immuno-oncology and targeted cancer medicines, for $38.00 per share in cash. After subtracting relevant transaction fees and expenditures, Amgen will pay approximately $1.9 billion in total consideration to complete the tender offer and subsequent merger.
• Bayer acquires Asklepios BioPharmaceutical (AskBio) in December 2020 and introduces a new cell and gene therapy platform within the Pharmaceuticals Division. Bayer is now one of the industry's leaders in this rapidly expanding field.
• In November 2020, Novo Nordisk A/S announced the signing of a formal agreement to acquire Emisphere Technologies Inc. (Emisphere), a drug delivery firm with proprietary technologies, such as the Eligen(R) SNAC technology, that enable therapeutic oral formulations.
• Product Launches and Product Expansions
• Promacta, the first-line treatment for aplastic anemia, was approved by the Food and Drug Administration (FDA) in November 2018. Novartis AG introduced it. Novartis AG recently gained permission for Revolade, which is used to treat aplastic anemia in adults.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ACQUIRED APLASTIC ANEMIA MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ACQUIRED APLASTIC ANEMIA MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ACQUIRED APLASTIC ANEMIA MARKET, BY TYPE

• 5.1 Overview
• 5.2 Diagnosis
• 5.3 Treatment

6 GLOBAL ACQUIRED APLASTIC ANEMIA MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Hospitals
• 6.3 Clinics
• 6.4 Other

7 GLOBAL ACQUIRED APLASTIC ANEMIA MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East

8 GLOBAL ACQUIRED APLASTIC ANEMIA MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Pfizer Inc.
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Bayer AG
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Novo Nordisk AS
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Shire
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 SOBI
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Octapharma
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 CSL Limited
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Amgen Inc.
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 GlaxoSmithKline plc.
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Bluebird bio
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 Appendix

• 10.1 Related Research